RxDoctor Payments Data

David Wolfe, MD

Rheumatology · Chevy Chase, MDNPI 1104825249

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,116 of the $1,306 with a category attached, or 85.4%. Intuitive Surgical accounts for 85.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $1,261 and has fallen 98.4% since, to $20 in 2022. That places this record below the midpoint for rheumatology clinicians in MD, where the typical reported total is $2,316.

$1,306in general payments, 2019–2025

Across 14 payments — averaging $93.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Johnson & Johnson$170
  • Amgen$20
$231,380in research payments, 2019–2025

Across 5 payments — averaging $46,276 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$231K

What the payments were for

  • Travel & lodging$1,11685%
  • Food & beverage$17013%
  • Education$202%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical3$1,116
Johnson & Johnson10$170
Amgen1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,306 in reported general payments places this provider in the 35th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$2,695,899
Medicare patients
1,291
Services billed
121,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept15$229,970
Humira(Cf) PenAdalimumab26$192,816
HumiraAdalimumab15$120,410
EnbrelEtanercept16$117,098
Humira(Cf)Adalimumab12$78,752
KevzaraSarilumab11$55,471
OtrexupMethotrexate/Pf14$11,993
Hydroxychloroquine Sulfate145$5,872
MethotrexateMethotrexate Sodium131$4,712
Colchicine43$2,641
Prednisone147$1,507
Alendronate Sodium118$1,228
Allopurinol103$1,191
Celecoxib49$1,037
Gabapentin91$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$20$117,09816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →